This fact proves that efficacious, high-quality drugs are not solely made in the United States and Europe, but that any company committed to innovation and quality can become a top contender in the global pharmaceutical market.
As it has been pointed out before, Mexican pharmaceutical companies need backup from the government in the form of financial incentives or laws that benefit the development of this industry in the country. A combination of factors that include lack of funding and limited numbers of researchers in the field has stalled the growth of this industry in the past, but companies like Psicofarma have thrived despite the unfavorable circumstances.
Psicofarma, part of group Neolpharma, is dedicated to improving the lives of people suffering psychological and neurological disorders. It develops specialized drugs to treat chronic degenerative diseases such as depression, schizophrenia, bipolar disease, Parkinson's disease, and epilepsy. One of their products,. With a portfolio of more than 28 products and a production plant in Ecuador, this company has become one of the most important drug companies in Latin America.
This company strives for excellence by combining human talent with technological infrastructure and research development. In addition, the company has partnered with the Mexican Institute of Psychiatry, the National Institute of Neurology and Neurosurgery, and the Institute of Biomedical Research at UNAM with the aim of positioning Mexican patents in the hands of international clients.
Psicofarma's president, EfrÃ©n Ocampo LÃ³pez will speak about the way innovation has positioned his company as the leader in the development of specialized drugs in Mexico.
Join is in BioPharma Mexico this October to hear about way innovation is helping Mexican companies to become front runners in the global pharmaceutical industry.